These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 23830772)
1. Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection. Otto S; Baumann S; Ehrenfeld M; Pautke C J Craniomaxillofac Surg; 2013 Oct; 41(7):694-8. PubMed ID: 23830772 [TBL] [Abstract][Full Text] [Related]
2. Denosumab-associated osteonecrosis of the jaw--a case report. Vyas S; Hameed S; Murugaraj V Dent Update; 2014 Jun; 41(5):449-50. PubMed ID: 25073227 [TBL] [Abstract][Full Text] [Related]
3. Denosumab-related osteonecrosis of the jaw. Diz P; López-Cedrún JL; Arenaz J; Scully C J Am Dent Assoc; 2012 Sep; 143(9):981-4. PubMed ID: 22942143 [TBL] [Abstract][Full Text] [Related]
4. Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study. Pautke C; Bauer F; Otto S; Tischer T; Steiner T; Weitz J; Kreutzer K; Hohlweg-Majert B; Wolff KD; Hafner S; Mast G; Ehrenfeld M; Stürzenbaum SR; Kolk A J Oral Maxillofac Surg; 2011 Jan; 69(1):84-91. PubMed ID: 20971542 [TBL] [Abstract][Full Text] [Related]
5. Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases. O'Halloran M; Boyd NM; Smith A Aust Dent J; 2014 Dec; 59(4):516-9. PubMed ID: 25131835 [TBL] [Abstract][Full Text] [Related]
6. Review of current literature and implications of RANKL inhibitors for oral health care providers. Epstein MS; Ephros HD; Epstein JB Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Dec; 116(6):e437-42. PubMed ID: 22901640 [TBL] [Abstract][Full Text] [Related]
7. Stage 0 osteonecrosis of the jaw in a patient on denosumab. Aghaloo TL; Dry SM; Mallya S; Tetradis S J Oral Maxillofac Surg; 2014 Apr; 72(4):702-16. PubMed ID: 24397946 [TBL] [Abstract][Full Text] [Related]
8. Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab. Neuprez A; Coste S; Rompen E; Crielaard JM; Reginster JY Osteoporos Int; 2014 Jan; 25(1):393-5. PubMed ID: 23835864 [TBL] [Abstract][Full Text] [Related]
9. Denosumab osteonecrosis of the mandible: a new entity? A case report. Pichardo SE; Kuypers SC; van Merkesteyn JP J Craniomaxillofac Surg; 2013 Jun; 41(4):e65-9. PubMed ID: 23265807 [TBL] [Abstract][Full Text] [Related]
10. Surgery Combined with LPRF in Denosumab Osteonecrosis of the Jaw: Case Report. Maluf G; Pinho MC; Cunha SR; Santos PS; Fregnani ER Braz Dent J; 2016; 27(3):353-8. PubMed ID: 27224573 [TBL] [Abstract][Full Text] [Related]
11. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Taylor KH; Middlefell LS; Mizen KD Br J Oral Maxillofac Surg; 2010 Apr; 48(3):221-3. PubMed ID: 19836866 [TBL] [Abstract][Full Text] [Related]
12. Intraoperative efficiency of fluorescence imaging by Visually Enhanced Lesion Scope (VELscope) in patients with bisphosphonate related osteonecrosis of the jaw (BRONJ). Assaf AT; Zrnc TA; Riecke B; Wikner J; Zustin J; Friedrich RE; Heiland M; Smeets R; Gröbe A J Craniomaxillofac Surg; 2014 Jul; 42(5):e157-64. PubMed ID: 24011463 [TBL] [Abstract][Full Text] [Related]
13. Avascular mandibular osteonecrosis in association with bisphosphonate therapy: a report on four patients. Friedrich RE; Blake FA Anticancer Res; 2007; 27(4A):1841-5. PubMed ID: 17649782 [TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy. A critical review. Vescovi P; Nammour S Minerva Stomatol; 2010 Apr; 59(4):181-203, 204-13. PubMed ID: 20360666 [TBL] [Abstract][Full Text] [Related]
15. Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients. Voss PJ; Joshi Oshero J; Kovalova-Müller A; Veigel Merino EA; Sauerbier S; Al-Jamali J; Lemound J; Metzger MC; Schmelzeisen R J Craniomaxillofac Surg; 2012 Dec; 40(8):719-25. PubMed ID: 22336489 [TBL] [Abstract][Full Text] [Related]
16. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease. Sivolella S; Lumachi F; Stellini E; Favero L Anticancer Res; 2013 May; 33(5):1793-7. PubMed ID: 23645723 [TBL] [Abstract][Full Text] [Related]
17. Surgical treatment of jaw osteonecrosis in "Krokodil" drug addicted patients. Poghosyan YM; Hakobyan KA; Poghosyan AY; Avetisyan EK J Craniomaxillofac Surg; 2014 Dec; 42(8):1639-43. PubMed ID: 24969764 [TBL] [Abstract][Full Text] [Related]
18. Bone regeneration without bone grafting after resection of a segment of the mandible to treat bisphosphonate-related osteonecrosis of the jaw. Wilde F; Hendricks J; Riese C; Pausch NC; Schramm A; Heufelder M J Oral Maxillofac Surg; 2011 Oct; 69(10):2657-62. PubMed ID: 21741741 [No Abstract] [Full Text] [Related]
19. Tetracycline bone fluorescence: a valuable marker for osteonecrosis characterization and therapy. Pautke C; Bauer F; Bissinger O; Tischer T; Kreutzer K; Steiner T; Weitz J; Otto S; Wolff KD; Stürzenbaum SR; Kolk A J Oral Maxillofac Surg; 2010 Jan; 68(1):125-9. PubMed ID: 20006166 [TBL] [Abstract][Full Text] [Related]
20. Bisphosphonate-induced osteonecrosis of the jaw in a rat model arises first after the bone has become exposed. No primary necrosis in unexposed bone. Abtahi J; Agholme F; Sandberg O; Aspenberg P J Oral Pathol Med; 2012 Jul; 41(6):494-9. PubMed ID: 22268631 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]